Compare · MEDP vs MXCT
MEDP vs MXCT
Side-by-side comparison of Medpace Holdings Inc. (MEDP) and MaxCyte Inc. (MXCT): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MEDP and MXCT operate in Biotechnology: Commercial Physical & Biological Resarch (Health Care), so they compete in similar markets.
- MEDP is the larger of the two at $13.18B, about 108.0x MXCT ($122.1M).
- Over the past year, MEDP is up 55.3% and MXCT is down 47.4% - MEDP leads by 102.7 points.
- MEDP has been more active in the news (4 items in the past 4 weeks vs 1 for MXCT).
- MEDP has more recent analyst coverage (25 ratings vs 11 for MXCT).
- Company
- Medpace Holdings Inc.
- MaxCyte Inc.
- Price
- $461.89-1.24%
- $1.13-2.16%
- Market cap
- $13.18B
- $122.1M
- 1M return
- +11.14%
- +7.62%
- 1Y return
- +55.26%
- -47.44%
- Industry
- Biotechnology: Commercial Physical & Biological Resarch
- Biotechnology: Commercial Physical & Biological Resarch
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2016
- 2021
- News (4w)
- 4
- 1
- Recent ratings
- 25
- 11
Medpace Holdings Inc.
Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It also provides clinical development services to the biotechnology, pharmaceutical, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services. The company also provides bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. Medpace Holdings, Inc. was founded in 1992 and is based in Cincinnati, Ohio.
MaxCyte Inc.
MaxCyte, Inc. operates as a cell-based therapies and life sciences company in the United States and internationally. Its transfection systems include MaxCyte STX, a scalable transfection system that uses flow electroporation technology for the engineering of cells for a range of applications; MaxCyte VLX, an instrument for large volume cell-engineering; and MaxCyte GT, a non-viral cell-engineering technology designed for clinical use. The company also provides single use sterile processing assemblies; and proprietary electroporation buffers; and ExPERT brand series of instruments and consumables, as well as insourcing services. In addition, it develops CARMA, a novel and proprietary technology for the development of non-viral, human messenger RNA-based, chimeric antigen receptor or T-cell receptor redirected immune cell therapies. The company licenses and sells its instruments and technology; and sells its products to drug developers and biopharmaceutical companies. It has a clinical and commercial license agreement with Allogene Therapeutics, Inc. The company was founded in 1998 and is headquartered in Gaithersburg, Maryland.
Latest MEDP
- Medpace Holdings, Inc. to Report Second Quarter 2026 Financial Results on July 22, 2026
- New insider Hansman Brad W. claimed ownership of 697 shares (SEC Form 3)
- SEC Form 8-K filed by Medpace Holdings Inc.
- General Counsel & Corp. Secy. Ewald Stephen P exercised 16,349 shares at a strike of $138.87 and sold $7,357,050 worth of shares (16,349 units at $450.00) (SEC Form 4)
- SEC Form 8-K filed by Medpace Holdings Inc.
- SEC Form 4 filed by Director Zander Dani S.
- SEC Form 4 filed by Director Mccarthy Cornelius P. Iii
- SEC Form 4 filed by Director Kraft Robert O.
- SEC Form 4 filed by Director Gwadry-Sridhar Femida H.
- SEC Form 4 filed by Director Davenport Fred B Jr
Latest MXCT
- SEC Form 8-K filed by MaxCyte Inc.
- SEC Form 10-Q filed by MaxCyte Inc.
- MaxCyte Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
- MaxCyte Reports First Quarter 2026 Financial Results and Reiterates Full Year 2026 Guidance
- SEC Form DEFA14A filed by MaxCyte Inc.
- SEC Form DEF 14A filed by MaxCyte Inc.
- MaxCyte to Report First Quarter 2026 Financial Results on May 12, 2026
- SEC Form 4 filed by Ahuja Parmeet
- SEC Form S-8 filed by MaxCyte Inc.
- SEC Form 4 filed by Ahuja Parmeet